A promising experimental vaccine strategy, just entering clinical trials, displays a deleterious effect in mice. Use of antibodies to CD40 seems to clamp down on the long-term ability of T cells to respond to antigen (pages 354–360).
- John B A G Haanen
- Ton N M Schumacher